BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021.

Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for cancer, autoimmune and genetic blood disorders, today announced that new data will be presented from a single-center Phase 2 trial and a multi-center Phase 1b trial at the American Society of Hematology (ASH) Annual Meeting.

The Allen Institute announced the launch of the Allen Institute for Neural Dynamics, a new neuroscience research division focused on the mammalian brain’s computations that give rise to complex behaviors like decision making, learning and memory.

Sobi™ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021 .

The Flume Catheter Company Ltd. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the FLUME catheter in the United States.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, which will be held December 11-14, 2021.

Transgene today announces its business update for the quarter ending September 30, 2021.

Results from PROTECT Trial Evaluating KRYSTEXXA ® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week

The National Kidney Foundation, the leading kidney patient organization in the U.S., applauds the Centers for Medicare and Medicaid Services for protecting dialysis patients.

Cardiovascular Systems, Inc. announced today the start of enrollment in a first in-human trial of the coronary everolimus drug-coated balloon (DCB) being developed by Chansu Vascular Technologies, LLC (CVT).